Surgery Clinical Trial
Official title:
Effects of Photobiomodulation on Functional Recovery of Proximal Humerus Fractures: a Double-blind Randomized Controlled Clinical Study
This double-blind, randomized controlled clinical study aims to evaluate the effects of PBM on the functional recovery of participants with surgically treated PHF using special locking plates. The 42 participants will be randomized (1:1) into two groups: the Control group (standard physical therapy combined with simulated PBM) and the PBM group (standard physical therapy combined with active PBM). Participants will apply PBM at home daily for 10 minutes using a device containing 318 light-emitting diodes (LEDs), with 159 LEDs at 660 nm (28.5 mW; 12 J/cm2; 17 J per LED) and 159 LEDs at 850 nm (23 mW; 10 J/cm2; 14 J per LED). PBM and physical therapy sessions (30 minutes, twice a week) will be conducted over 12 weeks. Participants will be unaware of their group allocation and will be assessed at 24 hours, 1, 2, 4, 8, and 12 weeks after surgery by four examiners who are also blinded to each participant's allocation. The primary outcome, assessed at all time points, will be shoulder function recovery using the Quick-DASH functional scale. Secondary outcomes will include shoulder range of motion assessments with a digital goniometer, quality of life using the SF-6 questionnaire, and the occurrence of adverse effects at all time points. Spontaneous pain, pressure pain (measured with a dolorimeter), nighttime pain, and analgesic use will be evaluated at 1, 2, 4, 8, and 12 weeks. Fracture consolidation will be assessed at 4, 8, and 12 weeks through radiographic examinations, and muscle strength will be evaluated by progressive dumbbell support at 8 and 12 weeks. In addition to the scheduled assessments, participants will be contacted daily by phone.
Status | Not yet recruiting |
Enrollment | 42 |
Est. completion date | April 30, 2026 |
Est. primary completion date | December 30, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Subjects of both genders treated at the HMACN Hospital with isolated and closed proximal humerus fractures with displacement and surgical indication undergoing RAFI with an angular stable locked plate for the proximal humerus (Neer 1070, Carrerra et al. 2012, Petros 2019) will be selected for inclusion according to the following eligibility criteria. Individuals aged between 18 and 75, of both genders, with PHF classified as: - Neer Group II only in patients under 55 years old - Neer Group III - Neer Group IV - Neer Group V, 3 parts - Displaced fractures - AO/OTA subgroups A1.1, A2, and A3 - AO/OTA Group B - AO/OTA Group C only in patients under 55 years old. Individuals will be excluded if they: - Have pre-existing shoulder or scapular injuries or motor deficits resulting from central or peripheral neurological injuries. - Have pathological fractures. - Develop post-operative infection or implant loosening. - Have ipsilateral fractures in other limb regions. - Present neurovascular injury with sensory deficits at the site of the injury. - Have local or systemic conditions that contraindicate surgery or complicate the post-operative period. - Have a history of photosensitivity. - Have neurological and psychiatric disorders. - Have proliferative or infectious skin lesions in the shoulder area that will receive LED light. - Have used anti-inflammatories in the 5 days prior to the trauma. - Are pregnant. - Experience surgical complications such as neurological or vascular injuries, as well as fracture line extension during the surgical procedure, as they will not meet the desired standard of progress |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Nove de Julho |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quick-DASH functional scale | In this project, the dysfunction and symptom component of the QuickDASH score, validated for Brazil and available online, will be used.
The QuickDASH score is calculated as follows: At least 10 out of the 11 items must be answered. Each answered question will have a maximum value of 5. These values are then transformed into a score of 100 by subtracting 1 and multiplying by 25. This transformation is done to compare the scores with other scales ranging from 0 to 100. A high score indicates significant dysfunction. QuickDASH Score = [(Sum of responses / n) - 1] X 25 n: the number of questions answered. |
The QuickDASH will be applied at 1 weeks after the surgical procedure. | |
Primary | Quick-DASH functional scale | In this project, the dysfunction and symptom component of the QuickDASH score, validated for Brazil and available online, will be used.
The QuickDASH score is calculated as follows: At least 10 out of the 11 items must be answered. Each answered question will have a maximum value of 5. These values are then transformed into a score of 100 by subtracting 1 and multiplying by 25. This transformation is done to compare the scores with other scales ranging from 0 to 100. A high score indicates significant dysfunction. QuickDASH Score = [(Sum of responses / n) - 1] X 25 n: the number of questions answered. |
The QuickDASH will be applied at 2 weeks after the surgical procedure. | |
Primary | Quick-DASH functional scale | In this project, the dysfunction and symptom component of the QuickDASH score, validated for Brazil and available online, will be used.
The QuickDASH score is calculated as follows: At least 10 out of the 11 items must be answered. Each answered question will have a maximum value of 5. These values are then transformed into a score of 100 by subtracting 1 and multiplying by 25. This transformation is done to compare the scores with other scales ranging from 0 to 100. A high score indicates significant dysfunction. QuickDASH Score = [(Sum of responses / n) - 1] X 25 n: the number of questions answered. |
The QuickDASH will be applied at 4 weeks after the surgical procedure. | |
Primary | Quick-DASH functional scale | In this project, the dysfunction and symptom component of the QuickDASH score, validated for Brazil and available online, will be used.
The QuickDASH score is calculated as follows: At least 10 out of the 11 items must be answered. Each answered question will have a maximum value of 5. These values are then transformed into a score of 100 by subtracting 1 and multiplying by 25. This transformation is done to compare the scores with other scales ranging from 0 to 100. A high score indicates significant dysfunction. QuickDASH Score = [(Sum of responses / n) - 1] X 25 n: the number of questions answered. |
The QuickDASH will be applied at 8 weeks after the surgical procedure. | |
Primary | Quick-DASH functional scale | In this project, the dysfunction and symptom component of the QuickDASH score, validated for Brazil and available online, will be used.
The QuickDASH score is calculated as follows: At least 10 out of the 11 items must be answered. Each answered question will have a maximum value of 5. These values are then transformed into a score of 100 by subtracting 1 and multiplying by 25. This transformation is done to compare the scores with other scales ranging from 0 to 100. A high score indicates significant dysfunction. QuickDASH Score = [(Sum of responses / n) - 1] X 25 n: the number of questions answered. |
The QuickDASH will be applied at 12 weeks after the surgical procedure. | |
Secondary | Range of Motion | The passive range of motion of the shoulder on both sides will be assessed with the participant in an upright position. The maximum tolerated position for extension, flexion, abduction, adduction, external rotation, and internal rotation will be noted by the evaluator. Rotations will be evaluated at 0° of abduction and flexion (Gracitelli 2015, Tenor Junior et al 2016). All measurements will be performed with a digital goniometer (Kaptron 360, Shenzhen, Dongguan China). | Range of motion will be assessed after 1 day of the surgical procedure | |
Secondary | Range of Motion | The passive range of motion of the shoulder on both sides will be assessed with the participant in an upright position. The maximum tolerated position for extension, flexion, abduction, adduction, external rotation, and internal rotation will be noted by the evaluator. Rotations will be evaluated at 0° of abduction and flexion (Gracitelli 2015, Tenor Junior et al 2016). All measurements will be performed with a digital goniometer (Kaptron 360, Shenzhen, Dongguan China). | Range of motion will be assessed after 1 week of the surgical procedure | |
Secondary | Range of Motion | The passive range of motion of the shoulder on both sides will be assessed with the participant in an upright position. The maximum tolerated position for extension, flexion, abduction, adduction, external rotation, and internal rotation will be noted by the evaluator. Rotations will be evaluated at 0° of abduction and flexion (Gracitelli 2015, Tenor Junior et al 2016). All measurements will be performed with a digital goniometer (Kaptron 360, Shenzhen, Dongguan China). | Range of motion will be assessed after 2 weeks of the surgical procedure | |
Secondary | Range of Motion | The passive range of motion of the shoulder on both sides will be assessed with the participant in an upright position. The maximum tolerated position for extension, flexion, abduction, adduction, external rotation, and internal rotation will be noted by the evaluator. Rotations will be evaluated at 0° of abduction and flexion (Gracitelli 2015, Tenor Junior et al 2016). All measurements will be performed with a digital goniometer (Kaptron 360, Shenzhen, Dongguan China). | Range of motion will be assessed after 4 weeks of the surgical procedure | |
Secondary | Range of Motion | The passive range of motion of the shoulder on both sides will be assessed with the participant in an upright position. The maximum tolerated position for extension, flexion, abduction, adduction, external rotation, and internal rotation will be noted by the evaluator. Rotations will be evaluated at 0° of abduction and flexion (Gracitelli 2015, Tenor Junior et al 2016). All measurements will be performed with a digital goniometer (Kaptron 360, Shenzhen, Dongguan China). | Range of motion will be assessed after 8 weeks of the surgical procedure | |
Secondary | Range of Motion | The passive range of motion of the shoulder on both sides will be assessed with the participant in an upright position. The maximum tolerated position for extension, flexion, abduction, adduction, external rotation, and internal rotation will be noted by the evaluator. Rotations will be evaluated at 0° of abduction and flexion (Gracitelli 2015, Tenor Junior et al 2016). All measurements will be performed with a digital goniometer (Kaptron 360, Shenzhen, Dongguan China). | Range of motion will be assessed after 12 weeks of the surgical procedure | |
Secondary | Muscle Strength | Muscle strength will be assessed by progressive holding of dumbbells with elbow flexion (RLM, Maringá, Paraná, Brazil), starting with 500 grams and progressing to 5 kg in the 8th and 12th weeks (Barbosa et al 2008). | 8th week of the surgical procedure | |
Secondary | Muscle Strength | Muscle strength will be assessed by progressive holding of dumbbells with elbow flexion (RLM, Maringá, Paraná, Brazil), starting with 500 grams and progressing to 5 kg in the 8th and 12th weeks (Barbosa et al 2008). | 12th week of the surgical procedure | |
Secondary | Pain Assessment | The intensity of spontaneous and function-related pain of the injured limb will be assessed using the visual analog pain scale (Jensen et al 1986). This scale consists of a 10 cm line with the phrases "absence of pain" and "unbearable pain" at the two extremes. | It will be evaluated at 1 week of the surgical procedure | |
Secondary | Pain Assessment | The intensity of spontaneous and function-related pain of the injured limb will be assessed using the visual analog pain scale (Jensen et al 1986). This scale consists of a 10 cm line with the phrases "absence of pain" and "unbearable pain" at the two extremes. | It will be evaluated at 2 weeks of the surgical procedure | |
Secondary | Pain Assessment | The intensity of spontaneous and function-related pain of the injured limb will be assessed using the visual analog pain scale (Jensen et al 1986). This scale consists of a 10 cm line with the phrases "absence of pain" and "unbearable pain" at the two extremes. | It will be evaluated at 4 of the surgical procedure | |
Secondary | Pain Assessment | The intensity of spontaneous and function-related pain of the injured limb will be assessed using the visual analog pain scale (Jensen et al 1986). This scale consists of a 10 cm line with the phrases "absence of pain" and "unbearable pain" at the two extremes. | It will be evaluated at 8 weeks of the surgical procedure | |
Secondary | Pain Assessment | The intensity of spontaneous and function-related pain of the injured limb will be assessed using the visual analog pain scale (Jensen et al 1986). This scale consists of a 10 cm line with the phrases "absence of pain" and "unbearable pain" at the two extremes. | It will be evaluated at 12 weeks of the surgical procedure | |
Secondary | Analgesic Consumption | The type and dosage of analgesics consumed will be inquired during the daily control of FBM use and will be recorded on the participant's daily control form. | It will be evaluated during a period of 12 weeks after surgical procedure | |
Secondary | SF-6 instrument | Quality of life will be assessed using the SF-6 instrument from 2002 in the version adapted for use in Brazil (Campolina et al 2011) at 1, 2, 4, 8, and 12 weeks, with the results recorded in the respective clinical records for each experimental period. | It will be evaluated at 1 week after surgical procedure | |
Secondary | SF-6 instrument | Quality of life will be assessed using the SF-6 instrument from 2002 in the version adapted for use in Brazil (Campolina et al 2011) at 1, 2, 4, 8, and 12 weeks, with the results recorded in the respective clinical records for each experimental period. | It will be evaluated at 2 weeks after surgical procedure | |
Secondary | SF-6 instrument | Quality of life will be assessed using the SF-6 instrument from 2002 in the version adapted for use in Brazil (Campolina et al 2011) at 1, 2, 4, 8, and 12 weeks, with the results recorded in the respective clinical records for each experimental period. | It will be evaluated at 4 weeks after surgical procedure | |
Secondary | SF-6 instrument | Quality of life will be assessed using the SF-6 instrument from 2002 in the version adapted for use in Brazil (Campolina et al 2011) at 1, 2, 4, 8, and 12 weeks, with the results recorded in the respective clinical records for each experimental period. | It will be evaluated at 8 weeks after surgical procedure | |
Secondary | SF-6 instrument | Quality of life will be assessed using the SF-6 instrument from 2002 in the version adapted for use in Brazil (Campolina et al 2011) at 1, 2, 4, 8, and 12 weeks, with the results recorded in the respective clinical records for each experimental period. | It will be evaluated at 12 weeks after surgical procedure | |
Secondary | Occurrence of Adverse Events | The occurrence of adverse events will be inquired during the daily control of FBM use and will be recorded on the participant's daily control form | It will be evaluated during a period of 12 weeks after surgical procedure | |
Secondary | Fracture Healing | Shoulder X-rays in the anteroposterior, scapular profile, and axillary incidences will be taken after 4, 8, and 12 weeks to assess bone healing, defined by the presence of a bony callus in 3 of the 4 bone cortices joining the main fracture fragments and compared with the X-ray taken immediately post-surgery (Gracitelli 2015). | It will be evaluated 4 weeks after surgical procedure | |
Secondary | Fracture Healing | Shoulder X-rays in the anteroposterior, scapular profile, and axillary incidences will be taken after 4, 8, and 12 weeks to assess bone healing, defined by the presence of a bony callus in 3 of the 4 bone cortices joining the main fracture fragments and compared with the X-ray taken immediately post-surgery (Gracitelli 2015). | It will be evaluated 8 weeks after surgical procedure | |
Secondary | Fracture Healing | Shoulder X-rays in the anteroposterior, scapular profile, and axillary incidences will be taken after 4, 8, and 12 weeks to assess bone healing, defined by the presence of a bony callus in 3 of the 4 bone cortices joining the main fracture fragments and compared with the X-ray taken immediately post-surgery (Gracitelli 2015). | It will be evaluated 12 weeks after surgical procedure | |
Secondary | Procedure-Related Costs | The costs of all procedures will be documented based on the Brazilian Unified Health System (SUS) price list | It will be evaluated during a period of 12 weeks after surgical procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Enrolling by invitation |
NCT05534490 -
Surgery and Functionality in Older Adults
|
N/A | |
Recruiting |
NCT04792983 -
Cognition and the Immunology of Postoperative Outcomes
|
||
Terminated |
NCT04612491 -
Pre-operative Consultation on Patient Anxiety and First-time Mohs Micrographic Surgery
|
||
Recruiting |
NCT06397287 -
PROM Project Urology
|
||
Recruiting |
NCT04444544 -
Quality of Life and High-Risk Abdominal Cancer Surgery
|
||
Completed |
NCT04204785 -
Noise in the OR at Induction: Patient and Anesthesiologists Perceptions
|
N/A | |
Completed |
NCT03432429 -
Real Time Tissue Characterisation Using Mass Spectrometry REI-EXCISE iKnife Study
|
||
Completed |
NCT04176822 -
Designing Animated Movie for Preoperative Period
|
N/A | |
Recruiting |
NCT05370404 -
Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain:
|
N/A | |
Not yet recruiting |
NCT05467319 -
Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS
|
Phase 3 | |
Recruiting |
NCT04602429 -
Children's Acute Surgical Abdomen Programme
|
||
Completed |
NCT03124901 -
Accuracy of Noninvasive Pulse Oximeter Measurement of Hemoglobin for Rainbow DCI Sensor
|
N/A | |
Completed |
NCT04595695 -
The Effect of Clear Masks in Improving Patient Relationships
|
N/A | |
Recruiting |
NCT06103136 -
Maestro 1.0 Post-Market Registry
|
||
Completed |
NCT05346588 -
THRIVE Feasibility Trial
|
Phase 3 | |
Completed |
NCT04059328 -
Novel Surgical Checklists for Gynecologic Laparoscopy in Haiti
|
||
Recruiting |
NCT03697278 -
Monitoring Postoperative Patient-controlled Analgesia (PCA)
|
N/A |